Cited by 260Cytokine Signaling Pathways and InteractionsPsoriasis: Treatment and PathogenesisT-cell and B-cell Immunology

Identification, Cloning, and Characterization of a Novel Soluble Receptor That Binds IL-22 and Neutralizes Its Activity

Kotenko, Sergei V, Izotova, Lara S, Mirochnitchenko, Olga V, Esterova, Elena, Dickensheets, Harold, Donnelly, Raymond P, Pestka, Sidney·2001·The Journal of Immunology

Abstract

With the use of a partial sequence of the human genome, we identified a gene encoding a novel soluble receptor belonging to the class II cytokine receptor family. This gene is positioned on chromosome 6 in the vicinity of the IFNGR1 gene in a head-to-tail orientation. The gene consists of six exons and encodes a 231-aa protein with a 21-aa leader sequence. The secreted mature protein demonstrates 34% amino acid identity to the extracellular domain of the IL-22R1 chain. Cross-linking experiments demonstrate that the protein binds IL-22 and prevents binding of IL-22 to the functional cell surface IL-22R complex, which consists of two subunits, the IL-22R1 and the IL-10R2c chains. Moreover, this soluble receptor, designated IL-22-binding protein (BP), is capable of neutralizing IL-22 activity. In the presence of the IL-22BP, IL-22 is unable to induce Stat activation in IL-22-responsive human lung carcinoma A549 cells. IL-22BP also blocked induction of the suppressors of cytokine signaling-3 (SOCS-3) gene expression by IL-22 in HepG2 cells. To further evaluate IL-22BP action, we used hamster cells expressing a modified IL-22R complex consisting of the intact IL-10R2c and the chimeric IL-22R1/γR1 receptor in which the IL-22R1 intracellular domain was replaced with the IFN-γR1 intracellular domain. In these cells, IL-22 activates biological activities specific for IFN-γ, such as up-regulation of MHC class I Ag expression. The addition of IL-22BP neutralizes the ability of IL-22 to induce Stat activation and MHC class I Ag expression in these cells. Thus, the soluble receptor designated IL-22BP inhibits IL-22 activity by binding IL-22 and blocking its interaction with the cell surface IL-22R complex.

Integrity signals

Registry

Crossref · 10.4049/jimmunol.166.12.7096

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • IL-22 mediates its functions by binding to its heterodimeric receptor consisting of IL-10 receptor β2 (IL-10Rβ2) and IL-22 receptor (IL-22R) and activating signaling pathways that stimulate STAT3 phosphorylation and nuclear translocation.

    “IL-22 mediates its functions by binding to its heterodimeric receptor consisting of IL-10 receptor β2 (IL-10Rβ2) and IL-22 receptor (IL-22R) and activating signaling pathways, which stimulate STAT3 phosphorylation and nuclear translocation.80–84”

    From The Innate Immune System in Acute and Chronic Wounds (2016) · cites this paper as [82]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Kotenko, S. V., Izotova, L. S., Mirochnitchenko, O. V., Esterova, E., Dickensheets, H., Donnelly, R. P., & Pestka, S.
Affiliations
  • Department of Molecular Genetics and Microbiology, University of Medicine and Dentistry, Robert Wood Johnson Medical School , Piscataway, NJ 08854
  • Center for Biologics Evaluation and Research (US)
Venue
The Journal of Immunology
Published
2001-06
Volume
166
Issue
12
Pages
7096-7103
ISSN
  • 0022-1767 (ISSN-L)
  • 1550-6606
OpenAlex
W1938903801
Cited by
260
References
32
Citations by year
2026: 1 · 2025: 3 · 2024: 10 · 2023: 12 · 2022: 6 · 2021: 15 · 2020: 16 · 2019: 10 · 2018: 19 · 2017: 11 · 2016: 14 · 2015: 12 · 2014: 11 · 2013: 12 · 2012: 10
FWCI
7.06
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Immunology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Cancer Institute (1P30-CA72720, R01 CA-46465, R01CA046465, P30CA072720)
  • National Institute of Allergy and Infectious Diseases (R01-AI43369, R01-AI36450, R01AI043369, R01AI036450)
Topics
  • Health Sciences › Medicine › Oncology › Cytokine Signaling Pathways and Interactions
  • Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
soluble receptor, IL-22, STAT activation, SOCS3, MHC class I expression, IFNGR1, chromosome 6, gene cloning
MeSH terms
Interleukin-22, Amino Acid Sequence, Animals, Base Sequence, Binding, Competitive, Carrier Proteins, Cloning, Molecular, Cricetinae, Humans, Interleukins, Ligands, Molecular Sequence Data, Receptors, Cell Surface, Solubility, Tumor Cells, Cultured, CHO Cells, DNA, Complementary, Receptors, Interleukin, COS Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review